Chikungunya Arthritis Still Lacks a Biomarker That Can Guide Treatment
Chikungunya arthritis remains a clinical syndrome in search of a validated precision tool. The review in Frontiers in Immunology argues that pain-dominant illness, periarticular inflammation, persistent synovitis, and rheumatoid arthritis-like presentations can look similar at the bedside while reflecting different biological states underneath. Symptom duration alone does not sort those states out, and the current biomarker literature has not delivered a marker that reliably predicts who will improve, who will persist, or who will benefit from a specific therapy.
The distinction matters because chikungunya virus infection does not end when fever resolves. Joint pain, stiffness, swelling, and functional loss can linger for months or years, and the residual disease burden can be substantial even after the acute viremic phase has passed. In that setting, a blood marker or imaging signal looks appealing, but plausibility is not proof. A cytokine elevation during active inflammation may simply mirror disease burden, while a viral signal in tissue does not automatically prove ongoing productive infection or a targetable cause of chronic pain.
Why Symptom Phase Alone Fails to Capture the Biology
The review separates clinical phenotype from proposed mechanistic endotype with unusual care. A phenotype is what clinicians can observe: tender joints, Doppler activity, tenosynovitis, rash, fatigue, or an RA-like pattern. An endotype is a hypothesis about the driver of disease, and in chikungunya arthritis those endotypes remain unvalidated. Patients can share the same calendar time after infection and still occupy different biological states, which is why a simple acute, subacute, chronic framework is too blunt for treatment selection.
That problem is not theoretical. Two patients may both be three months out from infection, yet one has severe pain without objective synovitis while another has inflammatory polyarthritis with imaging evidence of active disease. Those are not interchangeable states when corticosteroids, methotrexate, antivirals, neutralizing antibodies, or pathway-targeted immunomodulators are considered. The review emphasizes that any useful precision strategy must integrate disease phase, objective inflammation, functional burden, comorbidity, and alternative diagnoses rather than leaning on a single blood test.
Biomarkers Show Associations, Not Yet Treatment-Ready Prediction
Across the studies reviewed, the most consistent pattern is exploratory association rather than validated prediction. Some cohorts linked inflammatory mediators with concurrent symptoms; others suggested relationships with later arthralgia. Yet very few studies met the standards needed for a predictive biomarker, and none established a biomarker-by-treatment interaction. In practical terms, that means the field has not shown that marker-positive patients respond differently from marker-negative patients to a specific intervention.
The evidence base is further constrained by small sample sizes, heterogeneous assays, varying sampling windows, and incomplete external validation. Some studies relied on serum or plasma cytokines, others on stimulated peripheral blood mononuclear cell supernatants, and still others on imaging or autoantibody panels. Those methods answer different questions. A concurrent serum association with pain may describe active inflammation; a post-acute measurement associated with later disease is only a candidate prognostic marker; and a stimulated-cell readout cannot be treated as a serum cutoff that can be used in routine care.
A persistent cytokine signal is not enough to define a responder subgroup.
The review also makes clear that persistent antiviral antibodies, isolated cytokine elevations, or tissue viral RNA do not by themselves identify a biologically distinct and treatment-responsive group. Without cutoff validation, receiver operating characteristic performance in an external cohort, and reproducible calibration across laboratories, the markers remain research signals rather than clinical tools.
Methotrexate Has Some Support, but the Evidence Is Thin
The treatment section is cautious for good reason. Evidence for methotrexate remains limited by combination regimens, uncontrolled observations, and small comparative trials. In other words, the available studies do not cleanly isolate the effect of methotrexate itself from the effect of background therapies or from the natural history of a disease that can fluctuate over time. That makes it difficult to decide whether an apparent benefit reflects true disease modification or a mix of treatment, regression to the mean, and patient selection.
The same caution applies to proposed biomarker-directed therapy. Antivirals, neutralizing antibodies, and pathway-targeted immunomodulators remain investigational for chikungunya arthritis. Their biological rationale is understandable, especially if investigators can separate patients with ongoing inflammatory activity from those with pain amplification or non-inflammatory sequelae, but the review does not support routine biomarker-based selection today. The missing piece is a prospective trial that tests whether biomarker status changes the effect of treatment, not just whether biomarker levels correlate with symptoms.
What a Real Personalized-Therapy Program Would Need
The review sketches a research agenda rather than a ready-made clinical algorithm. Longitudinal cohorts need to track biomarker trajectories alongside objective inflammation, symptom burden, imaging, and function. Sampling time has to be standardized, because the meaning of a marker on day 2 of illness is different from its meaning at three months or years later. Assays also need harmonization across sites so that one laboratory’s signal can be compared with another’s.
Equally important, future studies have to distinguish prognostic from predictive utility. A prognostic marker tells clinicians who is more likely to develop persistent disease. A predictive marker tells clinicians who benefits more from one therapy than another. The current chikungunya literature mostly stops at the first question, and sometimes only at cross-sectional association. Until a biomarker-by-treatment interaction is demonstrated, personalized therapy remains an aspiration rather than a bedside option.
The review’s conclusion is clinically plain: current management still depends on phenotype recognition, objective assessment, and careful exclusion of alternative rheumatic disease. Biomarkers may eventually refine that process, but the field has not yet produced a validated marker that can direct therapy for chikungunya arthritis. The next decisive studies will need larger cohorts, prospective sampling, and treatment trials built to answer one question directly — whether a biomarker identifies a subgroup with a different clinical response.
- • Frontiers in Immunology DOI 10.3389/fimmu.2026.1959425: https://doi.org/10.3389/fimmu.2026.1959425